undamentalytics Newsletter
Sign in

Keros Therapeutics, Inc. income statement

In fiscal 2025, Keros Therapeutics, Inc. reported revenue of $244m, up 6769.4% on the year before, operating income of $67.6m (a 27.7% margin) and net income of $87.0m, or $2.30 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1002000424415
Research and development1734558713517413076
General and administrative313212835414741
Operating income−11−47−56−115−170−21168−101
Interest expense—00000——
Income before tax−12−46−57−105−153−18792−86
Income tax0−020005−3
Net income−12−45−59−105−153−18787−83
Diluted EPS−$6.08−$2.93−$2.52−$4.15−$5.20−$5.00$2.30−$3.05
Diluted shares (average)2m16m23m25m29m37m38m27m
EBITDA−10−46−56−114−169−21069−100

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ALEC vs KROSKROS vs LCTXKROS vs PRQR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Keros Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Keros Therapeutics, Inc.